Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes
用于监测基因组编辑结果的微生理人体组织系统
基本信息
- 批准号:9810917
- 负责人:
- 金额:$ 66.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAnimal ModelArchitectureBacteriaBiologyCRISPR/Cas technologyCell LineCell SurvivalCellsCellular ImmunityCellular Metabolic ProcessClinicalCommunicable DiseasesDNA Sequence AlterationDevelopmentDiseaseDisease modelDuchenne muscular dystrophyEnsureEvaluationGenesGenetic DiseasesGenomeGenome StabilityGenome engineeringGenomicsGoalsHumanHuman BiologyHuman EngineeringHuman GenomeHumoral ImmunitiesImmuneImmune responseImmune systemImmunityInjuryMethodsModificationMonitorMusMuscleMuscle DevelopmentMyocardiumNatural regenerationNon-Viral VectorNucleic AcidsOutcomePhysiologicalPhysiologyPluripotent Stem CellsPrevalenceProteinsResearch PersonnelRoleSeveritiesSiteSite-Directed MutagenesisSkeletal MuscleStem cellsSystemTechnologyTherapeuticTissue EngineeringTissuesTranslatingTranslationsTreatment EfficacyUnited States National Institutes of HealthViraladaptive immune responseadverse outcomedesigndrug discoveryexperimental studygenome analysisgenome editinggenome integritygenome-widehuman diseasehuman tissueinsightmicrophysiology systemmuscle formnew technologynovel strategiesresponsesomatic cell gene editingtherapy outcometissue regenerationtoolvector
项目摘要
Abstract:
Genome editing technologies have significant potential to treat a variety of devastating human diseases and
disorders. However, there are a number of challenges that genome editing therapies must overcome to reach
their full promise. Specifically, there are many possible adverse consequences that are unique to genome editing
tools, such as genome integrity, immune responses, and loss of therapeutic efficacy due to cell turnover, for
which there are currently are no optimal systems for rigorous assessment. Moreover, these consequences are
unique to human physiology, genome sequence, and immune systems, and therefore typical animal models are
not completely informative. To address this unmet need, we have assembled a team of collaborative
investigators that have developed advanced genome editing strategies and methods for engineering human
microphysiological tissue systems that recapitulate human physiology and function, with an emphasis on skeletal
and cardiac muscle. We will combine these technologies in this proposal to systemically evaluate tissue
physiology, genomic alterations, tissue regeneration, and immune response in response to various genome
editing strategies and delivery methods. Specifically, this will include comprehensive and unbiased mapping of
unintended modifications to human genome sequences, including at on-target and off-target sites. We will also
determine the role of resident tissue stem cells, cell turnover, and tissue injury and regeneration in the stability
of genome editing. Finally, we can incorporate immune cells into these microphysiological tissues to understand
the consequences of immunity to bacteria-derived genome editing components. Collectively, this proposal will
develop a platform to systematically address the most significant challenges to realizing the transformative
potential of genome editing therapies in human tissues.
抽象的:
基因组编辑技术具有治疗多种毁灭性人类疾病的巨大潜力
失调。然而,基因组编辑疗法必须克服许多挑战才能实现
他们的全部承诺。具体来说,基因组编辑特有的许多可能的不利后果
工具,例如基因组完整性、免疫反应以及由于细胞更新而导致的治疗功效丧失,
目前尚无最佳系统进行严格评估。而且,这些后果是
人类生理学、基因组序列和免疫系统所独有,因此典型的动物模型是
信息不完全。为了解决这一未满足的需求,我们组建了一个协作团队
研究人员开发了先进的基因组编辑策略和方法来工程人类
概括人体生理学和功能的微观生理组织系统,重点是骨骼
和心肌。我们将在本提案中结合这些技术来系统地评估组织
生理学、基因组改变、组织再生和对各种基因组的免疫反应
编辑策略和交付方法。具体来说,这将包括全面、公正地绘制
对人类基因组序列的意外修改,包括在目标位点和脱靶位点的修改。我们也会
确定常驻组织干细胞、细胞更新以及组织损伤和再生在稳定性中的作用
基因组编辑。最后,我们可以将免疫细胞整合到这些微生理组织中来了解
对细菌衍生的基因组编辑成分产生免疫力的后果。总的来说,该提案将
开发一个平台来系统地解决实现变革的最重大挑战
基因组编辑疗法在人体组织中的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nenad Bursac其他文献
Nenad Bursac的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nenad Bursac', 18)}}的其他基金
Engineering a Human Skeletal Muscle Tissue Model of LGMD2B
设计 LGMD2B 的人体骨骼肌组织模型
- 批准号:
10719721 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别:
Engineering Human Heart Tissues with Polyploid Cardiomyocytes
用多倍体心肌细胞改造人类心脏组织
- 批准号:
10467794 - 财政年份:2022
- 资助金额:
$ 66.82万 - 项目类别:
Engineered BacNav and BacCav for Improved Excitability and Contraction
专为改善兴奋性和收缩性而设计的 BacNav 和 BacCav
- 批准号:
10392121 - 财政年份:2022
- 资助金额:
$ 66.82万 - 项目类别:
Engineering Human Heart Tissues with Polyploid Cardiomyocytes
用多倍体心肌细胞改造人类心脏组织
- 批准号:
10616611 - 财政年份:2022
- 资助金额:
$ 66.82万 - 项目类别:
Engineered BacNav and BacCav for Improved Excitability and Contraction
专为改善兴奋性和收缩性而设计的 BacNav 和 BacCav
- 批准号:
10611385 - 财政年份:2022
- 资助金额:
$ 66.82万 - 项目类别:
Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes
用于监测基因组编辑结果的微生理人体组织系统
- 批准号:
10001507 - 财政年份:2019
- 资助金额:
$ 66.82万 - 项目类别:
Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes
用于监测基因组编辑结果的微生理人体组织系统
- 批准号:
10242833 - 财政年份:2019
- 资助金额:
$ 66.82万 - 项目类别:
Microphysiological Human Tissue Systems for Monitoring of Genome Editing Outcomes
用于监测基因组编辑结果的微生理人体组织系统
- 批准号:
10477016 - 财政年份:2019
- 资助金额:
$ 66.82万 - 项目类别:
Engineering of Human Excitable Tissues from Unexcitable Cells
从不可兴奋细胞改造人类可兴奋组织
- 批准号:
9270588 - 财政年份:2016
- 资助金额:
$ 66.82万 - 项目类别:
Engineering of Human Excitable Tissues from Unexcitable Cells
从不可兴奋细胞改造人类可兴奋组织
- 批准号:
9046968 - 财政年份:2016
- 资助金额:
$ 66.82万 - 项目类别:
相似国自然基金
肾—骨应答调控骨骼VDR/RXR对糖尿病肾病动物模型FGF23分泌的影响及中药的干预作用
- 批准号:82074395
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
基于细胞自噬调控的苦参碱对多囊肾小鼠动物模型肾囊肿形成的影响和机制研究
- 批准号:
- 批准年份:2019
- 资助金额:33 万元
- 项目类别:地区科学基金项目
靶向诱导merlin/p53协同性亚细胞穿梭对听神经瘤在体生长的影响
- 批准号:81800898
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
伪狂犬病病毒激活三叉神经节细胞对其NF-кB和PI3K/Akt信号转导通路影响的分子机制研究
- 批准号:31860716
- 批准年份:2018
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
基于中枢胰岛素抵抗探讨自噬失调对肾虚阿尔茨海默的影响及机制研究
- 批准号:81803854
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别:
Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels
通过针对 GIRK 通道进行 Dravet 综合征抗癫痫控制
- 批准号:
10638439 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
- 批准号:
10678062 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别:
Mechanisms of Metal Ion Homeostasis of Oral Streptococci
口腔链球菌金属离子稳态机制
- 批准号:
10680956 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别:
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
- 批准号:
10702126 - 财政年份:2023
- 资助金额:
$ 66.82万 - 项目类别: